Skip to Content

Cochlear Ltd CHEOF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of revenues where cochlear implants are the standard of care for children with severe to profound hearing loss. The company is actively targeting the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remainder 20% of revenues. Products include cochlear and other ear implants, bone-anchored hearing aids (BAHA) and associated sound processors. In fiscal 2020 49% of revenue came from the Americas, 36% from EMEA and 17% from the Asia-Pacific segment.

Contact
1 University Avenue, Macquarie University
Sydney, NSW, 2109, Australia
T +61 294286555
Sector Healthcare
Industry Medical Devices
Most Recent Earnings
Fiscal Year End Jun 30, 2021
Stock Type
Employees 4,000